Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Development of an antibody cocktail for treatment of Sudan virus infection.

Herbert AS, Froude JW, Ortiz RA, Kuehne AI, Dorosky DE, Bakken RR, Zak SE, Josleyn NM, Musiychuk K, Jones RM, Green B, Streatfield SJ, Wec AZ, Bohorova N, Bohorov O, Kim DH, Pauly MH, Velasco J, Whaley KJ, Stonier SW, Bornholdt ZA, Chandran K, Zeitlin L, Sampey D, Yusibov V, Dye JM.

Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3768-3778. doi: 10.1073/pnas.1914985117. Epub 2020 Feb 3.

PMID:
32015126
2.

Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.

Wec AZ, Bornholdt ZA, He S, Herbert AS, Goodwin E, Wirchnianski AS, Gunn BM, Zhang Z, Zhu W, Liu G, Abelson DM, Moyer CL, Jangra RK, James RM, Bakken RR, Bohorova N, Bohorov O, Kim DH, Pauly MH, Velasco J, Bortz RH 3rd, Whaley KJ, Goldstein T, Anthony SJ, Alter G, Walker LM, Dye JM, Zeitlin L, Qiu X, Chandran K.

Cell Host Microbe. 2019 Jan 9;25(1):39-48.e5. doi: 10.1016/j.chom.2018.12.004.

3.

Post-Exposure Protection in Mice against Sudan Virus by a Two Antibody Cocktail.

Froude JW, Herbert AS, Pelat T, Miethe S, Zak SE, Brannan JM, Bakken RR, Steiner AR, Yin G, Hallam TJ, Sato AK, Hust M, Thullier P, Dye JM.

Viruses. 2018 May 26;10(6). pii: E286. doi: 10.3390/v10060286.

4.

Design and evaluation of bi- and trispecific antibodies targeting multiple filovirus glycoproteins.

Nyakatura EK, Zak SE, Wec AZ, Hofmann D, Shulenin S, Bakken RR, Aman MJ, Chandran K, Dye JM, Lai JR.

J Biol Chem. 2018 Apr 20;293(16):6201-6211. doi: 10.1074/jbc.RA117.001627. Epub 2018 Mar 2.

5.

Mechanistic and Fc requirements for inhibition of Sudan virus entry and in vivo protection by a synthetic antibody.

Hofmann D, Zak SE, Nyakatura EK, Mittler E, Bakken RR, Chandran K, Dye JM, Lai JR.

Immunol Lett. 2017 Oct;190:289-295. doi: 10.1016/j.imlet.2017.09.002. Epub 2017 Sep 8.

6.

Antibodies from a Human Survivor Define Sites of Vulnerability for Broad Protection against Ebolaviruses.

Wec AZ, Herbert AS, Murin CD, Nyakatura EK, Abelson DM, Fels JM, He S, James RM, de La Vega MA, Zhu W, Bakken RR, Goodwin E, Turner HL, Jangra RK, Zeitlin L, Qiu X, Lai JR, Walker LM, Ward AB, Dye JM, Chandran K, Bornholdt ZA.

Cell. 2017 May 18;169(5):878-890.e15. doi: 10.1016/j.cell.2017.04.037.

7.

Generation and characterization of protective antibodies to Marburg virus.

Froude JW, Pelat T, Miethe S, Zak SE, Wec AZ, Chandran K, Brannan JM, Bakken RR, Hust M, Thullier P, Dye JM.

MAbs. 2017 May/Jun;9(4):696-703. doi: 10.1080/19420862.2017.1299848. Epub 2017 Mar 13.

8.

Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects.

Bekerman E, Neveu G, Shulla A, Brannan J, Pu SY, Wang S, Xiao F, Barouch-Bentov R, Bakken RR, Mateo R, Govero J, Nagamine CM, Diamond MS, De Jonghe S, Herdewijn P, Dye JM, Randall G, Einav S.

J Clin Invest. 2017 Apr 3;127(4):1338-1352. doi: 10.1172/JCI89857. Epub 2017 Feb 27.

9.

Recombinant proteins of Zaire ebolavirus induce potent humoral and cellular immune responses and protect against live virus infection in mice.

Lehrer AT, Wong TS, Lieberman MM, Humphreys T, Clements DE, Bakken RR, Hart MK, Pratt WD, Dye JM.

Vaccine. 2018 May 24;36(22):3090-3100. doi: 10.1016/j.vaccine.2017.01.068. Epub 2017 Feb 16.

PMID:
28216187
10.

A "Trojan horse" bispecific-antibody strategy for broad protection against ebolaviruses.

Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, Mittler E, Christin JR, Shulenin S, Jangra RK, Bharrhan S, Kuehne AI, Bornholdt ZA, Flyak AI, Saphire EO, Crowe JE Jr, Aman MJ, Dye JM, Lai JR, Chandran K.

Science. 2016 Oct 21;354(6310):350-354. Epub 2016 Sep 8.

11.

1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus.

Gupta P, Sharma A, Spurgers KB, Bakken RR, Eccleston LT, Cohen JW, Honnold SP, Glass PJ, Maheshwari RK.

Vaccine. 2016 May 27;34(25):2762-5. doi: 10.1016/j.vaccine.2016.04.049. Epub 2016 Apr 26.

PMID:
27129427
12.

Bispecific Antibody Affords Complete Post-Exposure Protection of Mice from Both Ebola (Zaire) and Sudan Viruses.

Frei JC, Nyakatura EK, Zak SE, Bakken RR, Chandran K, Dye JM, Lai JR.

Sci Rep. 2016 Jan 13;6:19193. doi: 10.1038/srep19193.

13.

Eastern equine encephalitis virus in mice II: pathogenesis is dependent on route of exposure.

Honnold SP, Mossel EC, Bakken RR, Lind CM, Cohen JW, Eccleston LT, Spurgers KB, Erwin-Cohen R, Glass PJ, Maheshwari RK.

Virol J. 2015 Sep 30;12:154. doi: 10.1186/s12985-015-0385-2.

14.

Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.

Bounds CE, Kwilas SA, Kuehne AI, Brannan JM, Bakken RR, Dye JM, Hooper JW, Dupuy LC, Ellefsen B, Hannaman D, Wu H, Jiao JA, Sullivan EJ, Schmaljohn CS.

PLoS One. 2015 Sep 30;10(9):e0137786. doi: 10.1371/journal.pone.0137786. eCollection 2015.

15.

Eastern equine encephalitis virus in mice I: clinical course and outcome are dependent on route of exposure.

Honnold SP, Mossel EC, Bakken RR, Fisher D, Lind CM, Cohen JW, Eccleston LT, Spurgers KB, Erwin-Cohen R, Bradfute SB, Maheshwari RK, Glass PJ.

Virol J. 2015 Sep 29;12:152. doi: 10.1186/s12985-015-0386-1.

16.

Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.

Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94. doi: 10.1093/infdis/jiv215. Epub 2015 May 4.

PMID:
25943199
17.

Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.

Reed DS, Glass PJ, Bakken RR, Barth JF, Lind CM, da Silva L, Hart MK, Rayner J, Alterson K, Custer M, Dudek J, Owens G, Kamrud KI, Parker MD, Smith J.

J Virol. 2014 Oct;88(20):12077-86. doi: 10.1128/JVI.01406-14. Epub 2014 Aug 13.

18.

Second generation inactivated eastern equine encephalitis virus vaccine candidates protect mice against a lethal aerosol challenge.

Honnold SP, Bakken RR, Fisher D, Lind CM, Cohen JW, Eccleston LT, Spurgers KB, Maheshwari RK, Glass PJ.

PLoS One. 2014 Aug 12;9(8):e104708. doi: 10.1371/journal.pone.0104708. eCollection 2014.

19.

Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.

Herbert AS, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, Olinger GG, Groebner JL, Lee JS, Pratt WD, Custer M, Kamrud KI, Smith JF, Hart MK, Dye JM.

J Virol. 2013 May;87(9):4952-64. doi: 10.1128/JVI.03361-12. Epub 2013 Feb 13.

20.

Designing and testing broadly-protective filoviral vaccines optimized for cytotoxic T-lymphocyte epitope coverage.

Fenimore PW, Muhammad MA, Fischer WM, Foley BT, Bakken RR, Thurmond JR, Yusim K, Yoon H, Parker M, Hart MK, Dye JM, Korber B, Kuiken C.

PLoS One. 2012;7(10):e44769. doi: 10.1371/journal.pone.0044769. Epub 2012 Oct 3.

21.

High-resolution functional mapping of the venezuelan equine encephalitis virus genome by insertional mutagenesis and massively parallel sequencing.

Beitzel BF, Bakken RR, Smith JM, Schmaljohn CS.

PLoS Pathog. 2010 Oct 14;6(10):e1001146. doi: 10.1371/journal.ppat.1001146.

22.

Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Apr 19;28(18):3143-51. doi: 10.1016/j.vaccine.2010.02.056. Epub 2010 Mar 1.

23.

Comparison of the immunological responses and efficacy of gamma-irradiated V3526 vaccine formulations against subcutaneous and aerosol challenge with Venezuelan equine encephalitis virus subtype IAB.

Martin SS, Bakken RR, Lind CM, Garcia P, Jenkins E, Glass PJ, Parker MD, Hart MK, Fine DL.

Vaccine. 2010 Jan 22;28(4):1031-40. doi: 10.1016/j.vaccine.2009.10.126. Epub 2009 Nov 13.

24.

Telemetric analysis to detect febrile responses in mice following vaccination with a live-attenuated virus vaccine.

Martin SS, Bakken RR, Lind CM, Reed DS, Price JL, Koeller CA, Parker MD, Hart MK, Fine DL.

Vaccine. 2009 Nov 16;27(49):6814-23. doi: 10.1016/j.vaccine.2009.09.013. Epub 2009 Sep 15.

Supplemental Content

Loading ...
Support Center